Introduction {#s1}
============

Periodontal Disease (PD) is a group of inflammatory diseases that affecting the supporting tissues of the teeth. At least approximately 35% dentate adults aged between 30 and 90 years old in the United States experience PD [@pone.0046508-Albandar1], and this disease can affect up to 90% of the global population [@pone.0046508-Pihlstrom1]. Based on the theory of "focal infection" which emerged at the beginning of the twentieth century, many studies have investigated a possible role for PD as a risk factor for systemic conditions over the past two decades [@pone.0046508-Cullinan1], including cardiovascular diseases [@pone.0046508-Blaizot1], diabetes [@pone.0046508-Preshaw1], adverse pregnancy outcome [@pone.0046508-Xiong1], osteoporosis [@pone.0046508-Megson1], rheumatoid arthritis [@pone.0046508-Detert1], and Chronic obstructive pulmonary disease (COPD) [@pone.0046508-Azarpazhooh1], [@pone.0046508-Scannapieco1].

COPD is the third leading cause of death in the United States, affecting as many as 24 million Americans and resulting in 700,000 hospital admissions, and 124,000 deaths annually [@pone.0046508-Corbridge1]. COPD is also an inflammatory disease characterized by the progressive deterioration of pulmonary function and increasing airway obstruction, includes chronic bronchitis and emphysema [@pone.0046508-Hill1]. In line with the relationship between the anatomical position of oral cavity and pulmonary infection, oral bacteria can be easily carried into the lung and cause infection [@pone.0046508-GomesFilho1].In addition, PD and COPD share the same risk factors, including smoking, age, obesity, socioeconomic status, and living conditions [@pone.0046508-Cullinan1]. These data strongly suggest that PD may be a risk factor for COPD and that oral bacteria may play a key role in its progression.

This hypothesis has received rapidly growing interest in the past years, and the relationship between PD and COPD has been increasingly recognized over the last two decades. Many epidemiological studies [@pone.0046508-Hayes1], [@pone.0046508-Scannapieco2], [@pone.0046508-Russell1], [@pone.0046508-Scannapieco3], [@pone.0046508-Garcia1], [@pone.0046508-Hyman1], [@pone.0046508-Kowalski1], [@pone.0046508-Leuckfeld1], [@pone.0046508-Deo1], [@pone.0046508-Fatemi1], [@pone.0046508-Wang1], [@pone.0046508-Prasanna1], [@pone.0046508-Si1], [@pone.0046508-Zhou1], [@pone.0046508-Katancik1], [@pone.0046508-Terpenning1], [@pone.0046508-Terpenning2], [@pone.0046508-Sharma1], [@pone.0046508-Mojon1], [@pone.0046508-Liu1], [@pone.0046508-Scannapieco4] have investigated the link between PD and risk of COPD, and most found a positive association. However, different studies have used different measurement methods and investigated different populations, and the magnitudes of the said association are varied and even contradictory among studies. Moreover, the possible role of PD in the pathogenesis of COPD remains an important but unresolved issue.

Two previous systematic reviews [@pone.0046508-Azarpazhooh1], [@pone.0046508-Scannapieco1] combined several epidemiological studies and reported an association between respiratory diseases and oral health, involving PD and COPD. One review [@pone.0046508-Azarpazhooh1] reported a weak association between PD and COPD based on two case-control studies [@pone.0046508-Hayes1], [@pone.0046508-Russell1] and two cross-sectional studies [@pone.0046508-Scannapieco2], [@pone.0046508-Scannapieco4] of poor to fair quality, whereas the other [@pone.0046508-Scannapieco1] demonstrated a potential association between PD and COPD based on one case-control studies [@pone.0046508-Hayes1] and three cross-sectional studies [@pone.0046508-Scannapieco2], [@pone.0046508-Garcia1], [@pone.0046508-Scannapieco4]. The evidence from each work is limited because only four studies were available and the conventional risk factors were not adjusted in the analysis. The presence of common conventional risk factors, such as smoking, renders the results questionable. Furthermore, whether PD is an independent risk factor for or merely a silent marker of COPD remains unclear.

An improved understanding of this issue may have important public health and clinical implications given the possibility that prevention and treatment of PD might reduce the incidence of COPD. The objectives of this study were to (1) evaluate the inconsistent results from published observational studies on the association between PD and risk of COPD by conducting a meta-analysis and (2) gain a more robust estimate association. We followed the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) [@pone.0046508-Moher1] guidelines to report this meta-analysis.

Methods {#s2}
=======

Literature search {#s2a}
-----------------

We initially identified published studies that investigated the association between PD and risk of COPD by searching the PubMed and Embase databases from their inception through to January 10, 2012. The following search terms were used: (1) "periodontal disease" or "paradontosis" or "parodontopathy" or "periodontal" or "gum disease" or "periodontium", and (2) "chronic obstructive pulmonary diseases" or "COPD" or "chronic bronchitis" or "emphysema", without restrictions. We also reviewed the reference lists of retrieved articles and recent reviews.

Study selection {#s2b}
---------------

We included any study that met all of the following criteria: (1) the study was of a cross-sectional, case-control, or cohort design; (2) clear diagnostic criteria for PD and COPD were established; (3) the association between PD and risk of COPD was investigated; and (4) the odds ratios (ORs)/risk ratio (RR, for cohort studies) and the corresponding 95% confidence intervals (CIs), or the number of events that can calculate them were reported. Two authors independently evaluated the eligibility of all studies retrieved from the databases. Disagreements were resolved by discussion or in consultation with a third author.

Data extraction {#s2c}
---------------

Two reviewers independently extracted data about the characteristics of each study by using a standardized data collection form. Data were recorded as follows: first author\'s last name, year of publication, country of origin; characteristics of study population and age at baseline; number of participants with PD and total number of participants, ascertainment of PD; assessment of COPD; and statistical adjustments for confounding factors. Any disagreements were resolved by consensus.

Statistical analysis {#s2d}
--------------------

We proposed that results from single studies be pooled by meta-analysis where this was found to be both clinically and statistically appropriate. We computed pooled ORs/RRs and relevant 95% CIs using Comprehensive Meta-Analysis software, Version 2.2 (Biostat, Englewood, NJ, USA) [@pone.0046508-Borenstein1] to generate forest plots, determine whether a statistical association between PD and risk of COPD exists, and assess the heterogeneity of the selected studies. Heterogeneity was quantified using the *I* ^2^ statistic [@pone.0046508-Higgins1], with the low, moderate, and high to *I* ^2^ values of 25%, 50%, and 75% respectively [@pone.0046508-Higgins2]. Where the *I* ^2^ value was 25% or lower, indicating no evidence of heterogeneity, we used the fixed-effect model; otherwise, we used the random-effects model.

In the presence of heterogeneity, we performed subgroup and sensitivity analyses to explore possible explanations for the heterogeneity and examine the influence of various exclusion criteria on the overall risk estimate. We also investigated the influence of a single study on the overall risk estimate by sequentially removing study to test the robustness of the main results.

Where possible, potential publication bias was assessed by visual inspection of the funnel plots of the primary outcome. The Egger linear regression test was used to examine the association between mean effect estimate and its variance [@pone.0046508-Egger1]. In addition, to assess the effect of possible publication bias, we calculated the number of unpublished studies that would have to exist to negate the results and the pooled OR adjusted for publication bias using the trim and fill method [@pone.0046508-Duval1].

Results {#s3}
=======

Study identification {#s3a}
--------------------

Of 179 records found initially, 14 articles involving 1 nested case-control study [@pone.0046508-Hayes1], 8 case-control studies [@pone.0046508-Russell1], [@pone.0046508-Kowalski1], [@pone.0046508-Deo1], [@pone.0046508-Fatemi1], [@pone.0046508-Wang1], [@pone.0046508-Prasanna1], [@pone.0046508-Si1], [@pone.0046508-Zhou1], and 5 cross-sectional studies [@pone.0046508-Scannapieco2], [@pone.0046508-Garcia1], [@pone.0046508-Hyman1], [@pone.0046508-Leuckfeld1], [@pone.0046508-Scannapieco4] were included in this meta-analysis. A detailed flowchart of the selection process is shown in [Figure 1](#pone-0046508-g001){ref-type="fig"}.

![Flow chart from identification of studies that tested the association between PD and risk of COPD to final inclusion.\
PD, periodontal dsease; COPD, chronic obstructive pulmonary disease.](pone.0046508.g001){#pone-0046508-g001}

Study characteristics {#s3b}
---------------------

[Table 1](#pone-0046508-t001){ref-type="table"} presents the major characteristics of the 14 studies for which information was available. These studies focused on COPD only. Sample sizes ranged from 58 to 13,792, representing 3,988 COPD patients and 22,871 controls subjects. One study provided results for males only [@pone.0046508-Hayes1], whereas another did for males in the COPD group and both sexes in the control group [@pone.0046508-Prasanna1]; data for 2 studies [@pone.0046508-Garcia1], [@pone.0046508-Fatemi1], and 10 others reported results for both sexes [@pone.0046508-Scannapieco2], [@pone.0046508-Russell1], [@pone.0046508-Hyman1], [@pone.0046508-Kowalski1], [@pone.0046508-Leuckfeld1], [@pone.0046508-Deo1], [@pone.0046508-Wang1], [@pone.0046508-Si1], [@pone.0046508-Zhou1], [@pone.0046508-Scannapieco4]. Of the principal studies, 6, 2, and 3 were conducted in the United States [@pone.0046508-Hayes1], [@pone.0046508-Scannapieco2], [@pone.0046508-Russell1], [@pone.0046508-Garcia1], [@pone.0046508-Hyman1], [@pone.0046508-Scannapieco4], India [@pone.0046508-Deo1], [@pone.0046508-Prasanna1], and China [@pone.0046508-Wang1], [@pone.0046508-Si1], [@pone.0046508-Zhou1], respectively; 1 study each was conducted in Poland [@pone.0046508-Kowalski1], Norway [@pone.0046508-Leuckfeld1], and Iran [@pone.0046508-Fatemi1].

10.1371/journal.pone.0046508.t001

###### Study characteristics of included studies.

![](pone.0046508.t001){#pone-0046508-t001-1}

  Refence                   Design   Location    Group    Subject    Age(yrs)     Gender(♂/♀)   Assessment of PD   Assessment of COPD                                                                 Adjustment for Covariates                                                                    OR(95%CI)
  ------------------------ -------- ---------- --------- --------- ------------- ------------- ------------------ -------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------
  Hayes et al 1998           NCC       USA       COPD       261      45.06±9.7       261/0            ABL                 FEV1                                                                   age, smoking, education, and height                                                            1.77(1,27,2.48)
                                                Control     857      42.18±9.1       857/0                                                                                                                                                                                                     
  Scannapieco et al 1998      CS       USA       COPD       77          NA           45/32            OHI            Self-reported                                                                               NA                                                                             4.5(1.06,18.99)
                                                Control     309                     137/172                                                                                                                                                                                                    
  Russell et al 1999          CC       USA       COPD       28       75.9±8.1        14/14             PI            Self-reported                                                                               NA                                                                             15(1.59,130.23)
                                                Control     30       75.1±5.9        12/18                                                                                                                                                                                                     
  Scannapieco et al 2001      CS       USA       COPD       810      51.2±17.9      304/506           CAL               FEV1/FVC         age, gender, race and ethnicity, and education, income, number of dental visits, pack years of smoking, alcohol consumption, and diabetes mellitus     1.45(1.02,2.05)
                                                Control   12,982     43.9±17.7    6,161/6,821                                                                                                                                                                                                  
  Garcia et al 2001           CS       USA       COPD       279         NA            NA              ABL                 FEV1                                                              age, height, smoking, alcohol, and education                                                        1.75(1.33,2.30)
                                                Control     833                                                                                                                                                                                                                                
  Hyman et al 2004            CS       USA       COPD       993     62.32±14.07   3,636/2,296         CAL            GOLD criteria      age, gender, race/ethnicity,history of hypertension, history of heart attack, dental visit within 1 year, body mass index, smoking, and family income   1.48(0.90,2.43)
                                                Control    6,632    47.37±14.23     371/662                                                                                                                                                                                                    
  Kowalski et al 2005         CC      Poland     COPD       100     63.1±10.17       68/32             PI               FEV1/FVC                                                                                 NA                                                                             3.59(1.84,6.98)
                                                Control     101     65.3±10.36       38/63                                                                                                                                                                                                     
  Leuckfeld 2008              CS      Norway     COPD       130      54.9±4.9        50/80            ABL            GOLD criteria                                                                    age, gender, and smoking                                                                  10.0(1.03,97.47)
                                                Control     50       47.0±9.8        29/21                                                                                                                                                                                                     
  Fatemi et al 2009           CC       Iran      COPD       30         53±7           NA              CAL                 PFT                                                                                    NA                                                                             1.80(1.46,2.22)
                                                Control     30         54±5                                                                                                                                                                                                                    
  Wang 2009                   CC      China      COPD       306     63.94±9.84      210/96            CAL            GOLD criteria                                                            age, gender, smoking, and body mass index                                                         1.00(0.99,1.01)
                                                Control     328     63.26±8.98      164/164                                                                                                                                                                                                    
  Deo et al 2009              CC      India      COPD       150     41.43±7.53      140/10            CAL               FEV1/FVC                                                                                 NA                                                                             1.11(0.79,1.56)
                                                Control     50       43.625.53       38/12                                                                                                                                                                                                     
  Prasanna 2011               CC      India      COPD       50       56.3±3.8        50/0              PI                 PFT                                                                                    NA                                                                             3.12(2.53,3.85)
                                                Control     50       47.4±4.9        27/23                                                                                                                                                                                                     
  Si et al 2012               CC      China      COPD       581      63.9±9.4       422/159            PI               FEV1/FVC                                                    age, gender, occupation, educational level and smoking status                                               9.01(3.98,20.40)
                                                Control     438      62.8±9.5       218/220                                                                                                                                                                                                    
  Zhou et al 2012             CC      China      COPD       193      63.6±10.3      132/61            ABL               FEV1/FVC                                                              age, gender, smoking, and body mass index                                                         1.34(0.66,2.73)
                                                Control     181      62.1±9.06      108/73                                                                                                                                                                                                     

NCC, nest case-control study; CS, cross-sectional study; CC, case-control study; NA, not available; ABL, alveolar bone loss; OHI, oral health index; PI, periodontal index; CAL, clinical attachment loss; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; GOLD criteria, Global Initiative for Chronic Obstructive Lung Disease spirometry guidelines; PFT, pulmonary function test, that means the article just mentioned but did not give what measurement have been used.

PD and risk of COPD {#s3c}
-------------------

[Figure 2](#pone-0046508-g002){ref-type="fig"} shows the results from the random-effects model pooling the ORs and 95% CIs for COPD. Of all 14 studies, four studies show there are no statistical differences [@pone.0046508-Hyman1], [@pone.0046508-Deo1], [@pone.0046508-Wang1], [@pone.0046508-Zhou1]; six studies show that population with PD face more than double risk of developing COPD compare with without ones [@pone.0046508-Scannapieco2], [@pone.0046508-Russell1], [@pone.0046508-Kowalski1], [@pone.0046508-Leuckfeld1], [@pone.0046508-Prasanna1], [@pone.0046508-Si1], and two studies show this times are ten or more [@pone.0046508-Russell1], [@pone.0046508-Leuckfeld1]. The overall meta-analysis of 14 studies identified a significantly increased risk of developing COPD (OR = 2.08, 95% CI = 1.48--2.91; *P*\<0.001). Substantial heterogeneity was observed (*I* ^2^ = 94.4%, *P*\<0.001).

![Forest plot of PD and risk of COPD, studies are pooled with random-effects model.\
The pooled OR was represented by a diamond of standard height, with the width indicating the 95% CI. PD, periodontal dsease; COPD, chronic obstructive pulmonary disease; OR, odds ratio; CI, confidence interval; NCC, nest case-control study; CC, case-control study; CS, cross-sectional study.](pone.0046508.g002){#pone-0046508-g002}

Subgroup and sensitivity analyses {#s3d}
---------------------------------

[Table 2](#pone-0046508-t002){ref-type="table"} shows the results of subgroup analyses by study design, ethnicity, assessment of PD, assessment of COPD, and adjustment for covariates. All these analyses indicated that PD is a risk factor for developing COPD, except for the clinical attachment loss (CAL) (OR = 1.32, 95% CI = 0.97--1.80; *P* = 0.07) and GOLD criteria (OR = 1.31, 95% CI = 0.76--2.24; *P* = 0.33). When stratified by adjustment for covariates, all the eight studies have adjusted smoking [@pone.0046508-Hayes1], [@pone.0046508-Garcia1], [@pone.0046508-Hyman1], [@pone.0046508-Leuckfeld1], [@pone.0046508-Wang1], [@pone.0046508-Si1], [@pone.0046508-Zhou1], [@pone.0046508-Scannapieco4], and the risk of adjusted studies is lower (OR = 1.78, 95% CI = 1.23--2.58; *P*\<0.001) than unadjusted ones (OR = 2.40, 95% CI = 1.52--3.81; *P*\<0.001), and the relevant 95%CI is also narrower. Sensitivity analysis was performed by sequentially removing each study. The significance of pooled ORs was not greatly influenced by the omission of any single study (the values of ORs are between 1.87 and 2.23, and the relevant 95%CIs are between 1.34 and 3.22), suggesting that the results of this meta-analysis are stable ([Fig. 3](#pone-0046508-g003){ref-type="fig"}).

![Forst plot of sensitivity analysis by removing each study in each turn.\
The pooled OR was represented by a diamond of standard height, with the width indicating the 95% CI. PD, periodontal dsease; COPD, chronic obstructive pulmonary disease; OR, odds ratio; CI, confidence interval; NCC, nest case-control study; CC, case-control study; CS, cross-sectional study.](pone.0046508.g003){#pone-0046508-g003}

10.1371/journal.pone.0046508.t002

###### Results of subgroups analyses of pooled ORs (95% CIs).

![](pone.0046508.t002){#pone-0046508-t002-2}

  Subgroups                    Num. of studies   Meta-analyses   Effect model   Heterogeneity                    
  --------------------------- ----------------- --------------- -------------- --------------- -------- -------- ---------
  Study design                                                                                                   
  NCC                                 1              2.77         1.27-2.47        \<0.001      fixed      0       1.00
  CC                                  8              2.26         1.38-3.70        \<0.001      random   96.33%   \<0.001
  CS                                  5              1.35         1.66-1.36        \<0.001      fixed    22.38%    0.27
  Ethnicity                                                                                                      
  North America                       6              1.69         1.43-2.00        \<0.001      fixed    25.30%    0.24
  Asia                                6              1.93         1.15-3.26        \<0.001      random   97.08%   \<0.001
  Europe                              2              3.89         2.05-7.38        \<0.001      fixed      0       0.40
  Assessment of PD                                                                                               
  ABL                                 4              1.74         1.42-2.13        \<0.001      fixed      0       0.42
  CAL                                 5              1.32         0.97-1.80         0.07        random   89.25%   \<0.001
  OHI                                 1              4.50         1.06-19.05        0.05        fixed      0       1.00
  PI                                  4              4.55         2.59-7.98        \<0.001      random   61.92%    0.05
  Assessment of COPD                                                                                             
  FEV1                                2              1.76         1.42-2.17        \<0.001      fixed      0       0.96
  FEV1/FEC                            5              2.18         1.19-4.01        \<0.001      random   85.62%   \<0.001
  GOLD criteria                       3              1.31         0.76-2.24         0.33        random   68.39%    0.04
  Self-reported                       2              6.46         1.93-21.60       \<0.001      fixed      0       0.37
  PFT                                 2              2.37         1.38-4.06        \<0.001      random   92.43%   \<0.001
  Adjustment for covariates                                                                                      
  Yes                                 8              1.78         1.23-2.58        \<0.001      random   89.42%   \<0.001
  NA                                  6              2.40         1.52-3.81        \<0.001      random   85.95%   \<0.001

NCC, nest case-control study; CS, cross-sectional study; CC, case-control study; NA, not available; ABL, alveolar bone loss; OHI, oral health index; PI, periodontal index; CAL, clinical attachment loss; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; GOLD criteria, Global Initiative for Chronic Obstructive Lung Disease spirometry guidelines; PFT, pulmonary function test, that means the article just mentioned but did not give what measurement have been used.

Publication bias {#s3e}
----------------

[Figure 4](#pone-0046508-g004){ref-type="fig"} shows that the funnel plot was asymmetrical, indicating the presence of publication bias. The Egger linear regression test also detected moderate publication bias among studies (OR = 3.43, 95%CI = 1.76--5.10; *P*\<0.001). As the evidence of bias could be due to inadequate statistical power, we used the non-parametric method of "trim and fill" and estimated two possible missing studies (black spots in [Fig. 4](#pone-0046508-g004){ref-type="fig"}). The estimated OR including the "missing" studies did not substantially different from our estimate with adjustment for missing studies (OR = 1.94, 95%CI = 1.40--2.70).

![Filled funnel plot with pseudo-95% CIs of results of 14 studies.\
Log of OR represents the natural logarithm of the OR of individual studies; Standard Error by Log odds ratio represents the standard error in the natural logarithm of the OR of individual studies. A circle in the figure represents a study, while a black spot represents an unpublished study that would have to exist to negate the results of the meta-analysis.](pone.0046508.g004){#pone-0046508-g004}

Discussion {#s4}
==========

COPD includes chronic bronchitis and emphysema, Murray et al has predicted that COPD would become the third most common cause of death and the fourth most important disease leading to disability by 2020 [@pone.0046508-Murray1], [@pone.0046508-Murray2]. PD is considered a novel risk factor, in addition to smoking, chronic exposure to hazardous air pollutants, and genetic conditions [@pone.0046508-Scannapieco5]. Our meta-analysis of one nested case-control study, eight case-control studies, and five cross-sectional studies provides evidence that PD is associated with an increased risk of COPD and can increase a significantly the risk by 2.08 times. When the subjects were stratified by ethnicity, this association did not differ: the ORs were 1.69 for North Americans (95%CI = 1.43--2.00), 1.93 for Asians (95%CI = 1.15--3.26), and 3.89 for Europeans (95%CI = 2.05--7.38). When the analysis was restricted to studies with control for conventional rsik factors, including age, gender, and especially smoking, PD was identified as a probable independent risk factor for COPD (OR = 1.78, 95%CI = 1.23--2.58; *P*\<0.001). When the groups were stratified the group by study design, the results also suggested that PD is a significant risk factor for COPD in both case-control and cross-sectional studies, with the association gaining more powerful from the cross-sectional studies (OR = 1.35, 95%CI = 1.66--1.36; *P*\<0.001) to the case-control studies (OR = 2.26, 95%CI = 1.38--3.70; *P*\<0.001) to the nested case-control study (OR = 2.77, 95%CI = 1.27--2.47; *P*\<0.001). This finding can be attributed to the fact that the cross-sectional study design suffers from more confounding biases compared with the case--control study design and the case--control study design suffers from more confounding biases compared with the nested case--control study design. The prospective cohort study design is the best among observational studies, and it can control confounding biases very well. We therefore suggest that this study design be used in future research.

Oral cavity has been recognized as a potential reservoir for respiratory pathogens [@pone.0046508-Mojon1], and dental plaque may play an important role in its formation, which may also contribute to PD [@pone.0046508-Coulthwaite1]. Colonization of dental plaque by respiratory pathogens followed by aspiration has been proposed as a possible mechanism, but data on whether the same pathogens are isolated in PD and COPD exacerbations are limited. Epidemiological studies have found evidence favoring this association; however, debate on this issue has ensued over recent decades. Our meta-analysis detected a significant association between PD and COPD with and without adjustments made on the conventional risk factors. This suggests that an effective oral hygiene regimen would effectively prevent the progression of COPD, and that an effective PD intervention treatment should be able to control COPD. Correct and effective brushing of teeth, use of dental floss, and regular periodontal scaling would be the simplest and most cost-effective actions. To substantiate these findings, we recommend that sufficient relevant randomized controlled trials be carried out to test whether periodontal interventions can affect the progression of COPD. Moreover, we suggest that fundamental studies investigating the true mechanism between PD and COPD be performed, particularly to identify which role or roles would take much of the responsibility and whether the pathogens isolated in PD exacerbations are the same as those isolated in COPD exacerbations --- which can give clearer guidelines for clinical practice and make the link between the two diseases more convincing. In addition, a spacer device and cold water for rinsing should be used in COPD patients undergoing treatment that requires steroid inhalation to reduce the accumulation of steroids in the mouth cavity; similarly, when a metered-dose inhaler is used for steroid inhalation, a spacer device should be applied to reduce the possibility for respiratory pathogens in dental plaque to move into the lung.

The main strength of this study was pooling data from individual studies with small sample sizes and a low statistical power via meta-analysis approach. We also collected studies as relevant as possible and used subgroup and sensitivity analyses to test the robustness of the results. This meta-analysis overcame the shortcomings of two pervious systematic reviews (our meta-analysis also included the five studies [@pone.0046508-Hayes1], [@pone.0046508-Scannapieco2], [@pone.0046508-Russell1], [@pone.0046508-Garcia1], [@pone.0046508-Scannapieco4] that used in those systematic reviews) [@pone.0046508-Azarpazhooh1], [@pone.0046508-Scannapieco1].

However, this study also had some limitations. First, although meta-analysis is a useful tool in epidemiology, problems associated with methodology may limit its benefits. Case-control study and cross-sectional studies are not the best designs among observational studies; thus, evidence from these studies is likely to be less accurate and possibly more influenced by recall bias compared with that from cohort studies. In addition, meta-analysis is a secondary analysis approach and has some inevitable biases. Second, some pooled ORs were obtained from heterogeneous studies, although we performed sensitivity analyses. Third, the funnel plot of publication bias showed that it was asymmetrical, and publication bias thus had to be considered. This suggests that we may have missed important unpublished studies with results inconsistent with our findings, although we did our best to collect all relevant studies. The filled funnel plot showed that two additional unpublished studiesare needed to negate the results of our meta-analysis. Fourth, none of the 14 studies were selected in our meta-analysis provided the degrees of PD and risk of COPD such that we could not conduct a dose-response analysis to assess their relationship more precisely. Fifth, the prevalence/incidence of COPD in developing countries (where access to dental care is limited) is presumably much higher than that in developed countries (where access to dental care is better), but we could not obtain current and relevant data to verify this. As PD and COPD share many risk factors, further research should analyze whether the association between them is causal using validated and optimal measurement tools (eg., Community Periodontal Index of Treatment Needs [@pone.0046508-Croxson1] for PD and FEV1/FVC for COPD [@pone.0046508-McKusick1]), calculate the interval between the onset of each disease, and consider adequate control for the confounding factors.

Conclusions {#s5}
===========

Based on current evidences, it can be concluded that: (1) PD significantly increases the risk of COPD, with the increase being likely independent of conventional COPD risk factors. However, the mechanisms still not clear. We suggest performing fundamental studies to investigate the true mechanism between PD and COPD. (2) Dental plaque that contains bacteria may be responsible for COPD, therefore, good attention to teeth brushing and general oral hygiene care may reduce the risk of COPD, and further studies are recommended to elucidate whether periodontal interventions can control the progression or reduce the incidence of COPD. (3) When using inhaled steroids treatment, COPD patients are suggested to use a spacer and rinse mouth with cold water. (4) An individual who is susceptible to COPD should pay close attention to his/her oral hygiene. It is suggested, for example, that the client brush twice a day with an antibacterial dentifrice, arrange for regular dental check-ups, and refrain from smoking. (5) An individual suffering from PD should seek treatment immediately and adhere to the doctor\'s orders concerning said treatment. (6) Those using removable dentures should clean them daily with/by polident, and those with permanent dentures should be examined at least every two years.

[^1]: **Competing Interests:**The authors have declared that no competing interests exist.

[^2]: Conceived and designed the experiments: XTZ WDL. Performed the experiments: XTZ MLT DYL. Analyzed the data: XTZ DZ. Contributed reagents/materials/analysis tools: XTZ. Wrote the paper: XTZ DZ JZ. Critically reviewed paper: MLT WDL.
